From Nasdaq: 2025-05-09 17:40:00

SpringWorks Therapeutics (SWTX) reported a quarterly loss of $1.11 per share, worse than the expected loss of $0.81. Revenues were $49.09 million, missing estimates by 23.53%. The stock has gained 27.9% this year. The company’s earnings outlook is favorable, with a Zacks Rank #2 (Buy). CytomX Therapeutics (CTMX) is also expected to release its results soon.



Read more at Nasdaq: SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates